-+ 0.00%
-+ 0.00%
-+ 0.00%

BioCardia says Japan PMDA advice clears path for CardiAMP approval filing in ischemic heart failure

PUBT·05/28/2026 12:04:58
Listen to the news
BioCardia says Japan PMDA advice clears path for CardiAMP approval filing in ischemic heart failure
  • BioCardia received a Japan PMDA consultation record supporting a regulatory submission to seek approval for CardiAMP cell therapy in ischemic HFrEF.
  • PMDA aligned on remaining submission items, including proof patients were on guideline-directed therapy, not eligible for revascularization, and more detail on major outcomes.
  • The company set a seven-month timeline for its PMDA filing, targeting an initial eligible pool of about 20,000 patients in Japan.
  • PMDA flagged post-marketing study expectations tied to patient selection, clinical decision-making, and specialist infrastructure, with MHLW issuing the commercialization certificate.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioCardia Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605280800PRIMZONEFULLFEED9727824) on May 28, 2026, and is solely responsible for the information contained therein.